| Name | Title | Contact Details |
|---|
Nobu, the world-renowned Japanese restaurant recognized for pioneering a new-style Japanese cuisine, started as a business partnership in 1994 between Chef Nobu Matsuhisa and his partners, Academy Award-winning actor Robert De Niro, producer Meir Teper, and restaurateur Drew Nieporent. Originating in New York as the flagship restaurant, the Nobu brand is now an empire that spans five continents with over 40 restaurants and growing. Following the success of the restaurants, Nobu Hospitality opened the first Nobu Hotel in 2013 in Las Vegas and today has 13 hotels open with several more in development.
Cobalt Sports Holdings was created to provide support, opportunities, collaboration and revenue streams to sports programs by combining the strength in numbers philosophy with clubs that are independent by structure and desire. These are sports programs that want to: Remain independent yet want to build programs that can retain players and coaches Compete at the highest levels Create exposure for players Be relevant at the local, state and national level events Continue to grow within their community. At Cobalt, we believe that EVERY club and EVERY player is relevant. That EVERY club deserves to thrive and that EVERY player should have multiple pathways as well as high-level coaching education opportunities. Pathways to the pros and pathways to college soccer. By combining like minded leaders running independent programs, a superior community of offerings is available to our members.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Our agency is the vision of a small group of insurance professionals who have spent years building large and mid-level risk management agencies. Mythic was born out of their desire to build an agency that caters to a select group of long-term clients who have an investment-minded view and value creativity and flexibility in a business partner. Although we have developed large specialty programs, such as our franchisor/franchisee risk management solution, we relish any opportunity to creatively craft custom risk management programs that mold to a clients specific needs. We offer expert guidance and flexibility to our clients, adjusting as their needs change and grow over time. Our ultimate goal is to make risk management and insurance profitable and as painless as possible.